Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J M Haro

Showing results (41-50 of 140) with videos related to

Pageof 14
Sort By:
Clinical Science (London, England : 1979)|October 1, 1991
Urinary excretion of digoxin-like immunoreactive factor and arginine-vasopressin in hyper- and hypo-thyroid ratsF Vargas, M J Baz, J D Luna, et al.
Acta Psychiatrica Scandinavica. Supplementum|November 8, 2006
Cost-effectiveness of different clinical interventions for reducing the burden of schizophrenia in SpainP Gutierrez-Recacha, D Chisholm, J M Haro, et al.
The Journal of Nervous and Mental Disease|June 1, 1993
Emotional distress in disaster victims. A follow-up studyB R Lima, S Pai, V Toledo, et al.
Journal of Affective Disorders|February 17, 2009
Pain and depression in older people: comorbidity and patterns of help seekingA Bonnewyn, C Katona, R Bruffaerts, et al.
Acta Psychiatrica Scandinavica|February 11, 2005
Olanzapine vs. other antipsychotics in actual out-patient settings: six months tolerability results from the European Schizophrenia Out-patient Health Outcomes studyM Lambert, J M Haro, D Novick, et al.
Pharmacopsychiatry|July 9, 2009
Translation of randomised controlled trial findings into clinical practice: comparison of olanzapine and valproate in the EMBLEM studyD Novick, A Gonzalez-Pinto, J M Haro, et al.
Life Sciences|January 1, 1991
Urinary excretion of digoxin-like immunoreactive factor and arginine-vasopressin in rats after several osmotic loadsF Vargas, J L Andrade, E Jódar, et al.
Schizophrenia Bulletin|January 1, 1992
Long-term course of hospitalization for schizophrenia: Part II. Change with passage of timeW W Eaton, W Bilker, J M Haro, et al.
Journal of Clinical Psychopharmacology|October 1, 1994
Haloperidol: therapeutic window in schizophreniaD J Palao, A Arauxo, M Brunet, et al.
Acta Psychiatrica Scandinavica|November 24, 1999
Service utilization and costs of first-onset schizophrenia in two widely differing health service areas in North-East Spain. PSICOST GroupL Salvador-Carulla, J M Haro, J Cabasés, et al.
Pageof 14

Showing results (41-50 of 140) with videos related to

Sort By:
Pageof 14
Clinical Science (London, England : 1979)|October 1, 1991
Urinary excretion of digoxin-like immunoreactive factor and arginine-vasopressin in hyper- and hypo-thyroid ratsF Vargas, M J Baz, J D Luna, et al.
Acta Psychiatrica Scandinavica. Supplementum|November 8, 2006
Cost-effectiveness of different clinical interventions for reducing the burden of schizophrenia in SpainP Gutierrez-Recacha, D Chisholm, J M Haro, et al.
The Journal of Nervous and Mental Disease|June 1, 1993
Emotional distress in disaster victims. A follow-up studyB R Lima, S Pai, V Toledo, et al.
Journal of Affective Disorders|February 17, 2009
Pain and depression in older people: comorbidity and patterns of help seekingA Bonnewyn, C Katona, R Bruffaerts, et al.
Acta Psychiatrica Scandinavica|February 11, 2005
Olanzapine vs. other antipsychotics in actual out-patient settings: six months tolerability results from the European Schizophrenia Out-patient Health Outcomes studyM Lambert, J M Haro, D Novick, et al.
Pharmacopsychiatry|July 9, 2009
Translation of randomised controlled trial findings into clinical practice: comparison of olanzapine and valproate in the EMBLEM studyD Novick, A Gonzalez-Pinto, J M Haro, et al.
Life Sciences|January 1, 1991
Urinary excretion of digoxin-like immunoreactive factor and arginine-vasopressin in rats after several osmotic loadsF Vargas, J L Andrade, E Jódar, et al.
Schizophrenia Bulletin|January 1, 1992
Long-term course of hospitalization for schizophrenia: Part II. Change with passage of timeW W Eaton, W Bilker, J M Haro, et al.
Journal of Clinical Psychopharmacology|October 1, 1994
Haloperidol: therapeutic window in schizophreniaD J Palao, A Arauxo, M Brunet, et al.
Acta Psychiatrica Scandinavica|November 24, 1999
Service utilization and costs of first-onset schizophrenia in two widely differing health service areas in North-East Spain. PSICOST GroupL Salvador-Carulla, J M Haro, J Cabasés, et al.
Pageof 14